{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Evaluation+only&page=2",
    "query": {
      "intervention": "Evaluation only",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Evaluation+only&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T09:20:56.348Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02263261",
      "title": "Evaluation of a Human Acellular Dermal Matrix in Post Mastectomy Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mastectomy",
        "Breast Reconstruction"
      ],
      "interventions": [
        {
          "name": "Flex HD Pliable Perforated HADM",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Musculoskeletal Transplant Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2015-03",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2018-09-20",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 2,
      "location_summary": "Mountain View, California • San Jose, California",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02263261"
    },
    {
      "nct_id": "NCT06176261",
      "title": "DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Female",
        "Metastatic Triple-Negative Breast Carcinoma",
        "ER Positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "HER2 Negative Breast Carcinoma",
        "ER-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Datopotamab Deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nancy Lin, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2024-01-08",
      "completion_date": "2029-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Boston, Massachusetts • Durham, North Carolina",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06176261"
    },
    {
      "nct_id": "NCT06544642",
      "title": "A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Sjögren's Syndrome"
      ],
      "interventions": [
        {
          "name": "ASP5502",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 116,
      "start_date": "2024-08-21",
      "completion_date": "2026-03-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06544642"
    },
    {
      "nct_id": "NCT01406470",
      "title": "Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immunologic Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Green Cross Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "2 Years to 70 Years"
      },
      "enrollment_count": 45,
      "start_date": "2011-09",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01406470"
    },
    {
      "nct_id": "NCT03231969",
      "title": "A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Bilastine 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Bilastine 0.4%",
          "type": "DRUG"
        },
        {
          "name": "Bilastine 0.6%",
          "type": "DRUG"
        },
        {
          "name": "Bilastine 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Faes Farma, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2017-07-20",
      "completion_date": "2017-10-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-16",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03231969"
    },
    {
      "nct_id": "NCT07763197",
      "title": "Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Muscle Invasive Bladder Cancer",
        "NMIBC",
        "High-risk Non-Muscle Invasive Bladder Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Natera, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2026-07-27",
      "completion_date": "2032-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07763197"
    },
    {
      "nct_id": "NCT01951560",
      "title": "A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Shock,Hemorrhagic"
      ],
      "interventions": [
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "Isotonic saline solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Hasan Alam",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2013-09",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-12-19",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951560"
    },
    {
      "nct_id": "NCT01757860",
      "title": "Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Safety",
        "Heart; Disease, Activity"
      ],
      "interventions": [
        {
          "name": "CARD-024",
          "type": "DRUG"
        },
        {
          "name": "Drug Carrier",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cardiavent Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 34,
      "start_date": "2011-09",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-12-31",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01757860"
    },
    {
      "nct_id": "NCT00676520",
      "title": "XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "XIENCE V® Everolimus Eluting Coronary Stent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 8053,
      "start_date": "2008-07",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2012-11-20",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 1,
      "location_summary": "Santa Clara, California",
      "locations": [
        {
          "city": "Santa Clara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676520"
    },
    {
      "nct_id": "NCT05789082",
      "title": "A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Divarasib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2023-06-20",
      "completion_date": "2032-01-29",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-09-25T09:20:56.348Z",
      "location_count": 16,
      "location_summary": "Duarte, California • Huntington Beach, California • Irvine, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05789082"
    }
  ]
}